G. Decrescenzo

发表

Physiochemical drug properties associated with in vivo toxicological outcomes.

J. Hughes, Enoch S. Huang, David A. Price, 2008, Bioorganic & medicinal chemistry letters.

A Physics-Based Current-Dependent Base Resistance Model For Advanced Bipolar-Transistors

G. Decrescenzo, J. Gupton, J. Idoux, 1985 .

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Manish R. Patel, R. Sullivan, K. Flaherty, 2017, Cancer discovery.

MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.

G. Decrescenzo, J. McDonald, C. Swearingen, 2010, Bioorganic & medicinal chemistry letters.

Inhibitors of HIV-1 protease containing the novel and potent (R)-(hydroxyethyl)sulfonamide isostere.

G. Decrescenzo, E. Doherty, M. Vazquez, 1995, Journal of medicinal chemistry.

Evaluation of 1-(2-deoxy-2-fluoro-1-d-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent

C. Bettegowda, S. Saha, G. Decrescenzo, 2014, World journal of microbiology & biotechnology.

alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.

G. Decrescenzo, P. Mehta, C. Swearingen, 2001, Bioorganic & medicinal chemistry letters.

Evaluation of 1-(2-deoxy-2-fluoro-1-d-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent

C. Bettegowda, S. Saha, G. Decrescenzo, 2014, World Journal of Microbiology and Biotechnology.

Regioselective Fluoroalkoxylation and Polyfluoroalkoxylation of Activated Polyhalobenzenes

G. Decrescenzo, J. Gupton, J. Idoux, 1984 .

A Reinvestigation of the Reaction of Hmpa With Ketoximes

G. Decrescenzo, J. Gupton, J. Idoux, 1983 .

Synthesis and Structure−Activity Relationships of β- and α-Piperidine Sulfone Hydroxamic Acid Matrix Metalloproteinase Inhibitors with Oral Antitumor Efficacy

C. Carron, G. Decrescenzo, P. Mehta, 2005 .

Selective functionalization of the C2 hydroxyl group of N-carbobenzyloxy-4,6--benzylidene-1-deoxynojirimycin

G. Decrescenzo, R. Heintz, D. Getman, 1991 .

Nucleophilic Opening of N-Carboalkoxy-2,3-anhydro-1-deoxymannojirimycin. A Useful Method for the Syntheses of 2-, 3- and 2,3-Disubstituted 1-Deoxynojirimycin Analogs

R. Mueller, I. Khanna, R. Weier, 1995 .

Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere.

R A Mueller, R. Mueller, J. Talley, 1993, Journal of medicinal chemistry.

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.

D. Dimitrov, S. Seaman, C. Szot, 2017, Cancer cell.

Tumor stroma‐targeted antibody‐drug conjugate triggers localized anticancer drug release

D. Dimitrov, S. Seaman, C. Szot, 2018, The Journal of clinical investigation.

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Paul Shapiro, Alex M Aronov, Mark Namchuk, 2017, Molecular Cancer Therapeutics.

Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors

R. Korn, S. Solomon, R. Murthy, 2020, Clinical Cancer Research.

Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.

Ying Yu, Gary A Decrescenzo, James R Kiefer, 2010, Journal of medicinal chemistry.

Abstract 4693: The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance

J. Roix, M. Garnett, C. Benes, 2015 .

SC-52151, a novel inhibitor of the human immunodeficiency virus protease

G. Decrescenzo, J. Marr, R. Dillard, 1995, Antimicrobial agents and chemotherapy.

Anti-CD 276-drug conjugates display potent anti-tumor and anti-metastatic activity d Pyrrolobenzodiazepine dimers are optimal warheads for targeting tumor

D. Dimitrov, S. Seaman, C. Szot, 2022 .

Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.

G. Decrescenzo, J. McDonald, T. Boehm, 2010, Bioorganic & medicinal chemistry letters.

Heterogeneity of Mediator Release From Human Basophils and Mast-cells Induced By Contrast-media (cm)

G. Marone, F. Tatangelo, G. Decrescenzo, 1994 .

Anticorps anti-cd276 (b7h3)

D. Dimitrov, S. Seaman, S. Saha, 2015 .

Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion

T. Sulpice, G. Decrescenzo, R. Halse, 2012, Diabetes, obesity & metabolism.

Synthesis and Structure−Activity Relationships of β- and α-Piperidine Sulfone Hydroxamic Acid Matrix Metalloproteinase Inhibitors with Oral Antitumor Efficacy

C. Carron, G. Decrescenzo, P. Mehta, 2005 .

α-Amino-β-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1

G. Decrescenzo, P. Mehta, C. Swearingen, 2001 .